Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients.

Respiratory investigation 2022 May

filter terms:

S-1, an oral fluoropyrimidine derivative, is widely used for the treatment of several solid tumors. However, there are no predictive markers for its effectiveness. We retrospectively screened 108 patients with advanced non-small cell lung cancer (NSCLC) treated via S-1 monotherapy and investigated its relationship with cytokeratin 19 fragment (CYFRA 21-1) and CEA pretreatment levels. Sixty-one patients with high CYFRA 21-1 levels had a statistically significant shorter progression-free survival (PFS) and overall survival (OS) than 46 patients with normal levels (median PFS = 42 days vs. 70 days, respectively; p = 0.0014; median OS = 197 days vs. 316 days, respectively, p = 0.0239). Serum CYFRA 21-1 levels have predictive and prognostic roles in the management of patients with advanced NSCLC on S-1 monotherapy. Copyright © 2022. Published by Elsevier B.V.

Citation

Yusuke Kagawa, Kazuki Sone, Tetsuya Oguri, Minoru Horiuchi, Satoshi Fukuda, Takehiro Uemura, Osamu Takakuwa, Ken Maeno, Kennsuke Fukumitsu, Yoshihiro Kanemitsu, Tomoko Tajiri, Hirotsugu Ohkubo, Masaya Takemura, Yutaka Ito, Akio Niimi. Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients. Respiratory investigation. 2022 May;60(3):393-399